GSK ups stake in Saudi business
FTSE 100 drugmaker Glaxosmithkline has lifted its stake in its Saudi Arabia business to 75pc from 49pc as the kingdom focuses on transforming the healthcare sector under its 2030 plan to reduce its reliance on oil. GSK also said it would be investing 900m riyals (£180m) in the Saudi unit over the next three years and expanding production.